Anticipated $-1.45 EPS for Esperion Therapeutics, Inc. (ESPR) on May, 3

Adjust Comment Print

Finally, Needham & Company LLC raised Esperion Therapeutics from a buy rating to a strong-buy rating and boosted their price objective for the stock from $72.00 to $81.00 in a research note on Thursday, December 14th. The institutional investor held 2.32 million shares of the health care company at the end of 2017Q4, valued at $152.94M, up from 2.29M at the end of the previous reported quarter.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The stock decreased 0.26% or $0.32 during the last trading session, reaching $120.75. About 26.23 million shares traded. Facebook, Inc. (NASDAQ:FB) has risen 8.48% since April 15, 2017 and is uptrending. It has outperformed by 17.84% the S&P500. Aqr Cap Ltd Company holds 25,380 shs or 0% of its capital. The institutional investor held 806,856 shares of the railroads company at the end of 2017Q4, valued at $108.20M, up from 644,056 at the end of the previous reported quarter. Moreover, Invesco has 0% invested in Esperion Therapeutics, Inc. Its shares touched $75.72 on during the last trading session after 1.97% change.Esperion Therapeutics, Inc. has volume of 369,096 shares. ESPR outperformed the S&P 500 by 78.31%. (NASDAQ:ESPR). Rothschild Asset Management reported 0.01% stake. (NASDAQ:ESPR). Caisse De Depot Et Placement Du Quebec holds 250,000 shs. Therefore 25% are positive. On Wednesday, October 18 the stock of Esperion Therapeutics, Inc. As per Friday, November 3, the company rating was downgraded by JP Morgan. (NYSE:TWX) on Thursday, December 14. On Wednesday, January 17 the firm has "Buy" rating given by UBS. The stock rating was maintained by Cowen & Co with "Buy" on Wednesday, March 7. (NASDAQ:ESPR) rating. Stifel Nicolaus has "Buy" rating and $105.0 target. On Wednesday, October 18 the company was maintained by Cowen & Co. (NASDAQ:ESPR) on Monday, January 22 to "Hold" rating.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.04, from 0.9 in 2017Q3.

Esperion Therapeutics Inc (NDAQ:ESPR) was upgraded by stock analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating in a report released on Tuesday, reports. Fmr Limited Liability Company, Massachusetts-based fund reported 121.64M shares. Perceptive Ltd Liability Company holds 0.02% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 67,241 shares. Susquehanna initiated it with "Positive" rating and $125 target in Monday, August 10 report. Swiss Bank & Trust reported 34,300 shares. Aimz Investment Advsrs Limited Co invested in 1.57% or 11,844 shares.

The holdings In Esperion Therapeutics Inc (ESPR) was upped owned by Rhenman & Partners Asset Management Ab. The Lodestar Investment Counsel Llc holds 55,444 shares with $4.02M value, down from 123,361 last quarter. Wafra Invest Advisory, New York-based fund reported 171,185 shares. (NASDAQ:ESPR). Citigroup Inc holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). C World Grp Incorporated A S invested in 0% or 4,433 shares. Amundi Pioneer Asset Management Inc. bought a new position in shares of Esperion Therapeutics during the 3rd quarter worth $9,517,000.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 20,871 shs.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.05, from 1 in 2017Q3. Rhumbline Advisers grew its holdings in shares of Esperion Therapeutics by 10.6% during the third quarter. 141 funds opened positions while 552 raised stakes. Hamilton Point Limited Liability has 5,357 shares for 0.38% of their portfolio. (NYSE:TWX) or 1,683 shares. 1,310 are held by Ameritas Prns Inc. Capital Guardian Co invested in 977,335 shares. Bailard reported 75,300 shs or 0.31% of all its holdings. Qs Invsts Limited Liability has 126,546 shares. Renaissance Techs Lc accumulated 0.08% or 389,700 shares. (NYSE:TWX). 20.88M are held by Dodge And Cox. Esperion Therapeutics has a one year low of $30.95 and a one year high of $82.68. (NYSE:V) to report earnings on April, 19. They expect $0.24 EPS, up 26.32% or $0.05 from last year's $0.19 per share. V's profit will be $2.28B for 29.89 P/E if the $1.01 EPS becomes a reality. During the same period in the prior year, the business posted ($1.29) earnings per share. analysts predict that Esperion Therapeutics will post -5.61 earnings per share for the current fiscal year.

Among 42 analysts covering Visa Inc. Therefore 56% are positive. Visa Inc. had 127 analyst reports since July 21, 2015 according to SRatingsIntel. Lake Street maintained the stock with "Buy" rating in Wednesday, June 29 report. The company was maintained on Friday, February 2 by BMO Capital Markets. The firm earned "Hold" rating on Friday, September 4 by Zacks. As per Monday, August 31, the company rating was maintained by Chardan Capital Markets. The stock of Visa Inc. The firm has "Outperform" rating given on Friday, November 6 by RBC Capital Markets. SunTrust maintained Visa Inc. Robert W. Baird has "Hold" rating and $124.0 target. UBS set a $90.00 price target on shares of Esperion Therapeutics and gave the company a "neutral" rating in a report on Wednesday, February 21st.

Since December 13, 2017, it had 0 insider purchases, and 3 sales for $6.56 million activity. $2.83M worth of Facebook, Inc.